Attention

The opinions expressed by columnists are their own and do not represent our advertisers

Saturday, April 06, 2019

JORDAN AND MEADOWS RAISE QUESTIONS ABOUT CUMMINGS’S DRUG PRICING INVESTIGATION

WASHINGTON, DC – Today, Congressman Jim Jordan (R-OH), Ranking Member of the Committee on Oversight and Reform, and Congressman Mark Meadows (R-NC), Ranking Member of the Government Operations Subcommittee, sent letters to twelve pharmaceutical companies targeted by Chairman Cummings’s sweeping drug price investigation.

Excerpts from the letter:
“Although addressing rising drug prices should be a bipartisan issue, Chairman Cummings did not consult with Republican Members before launching his investigation. Now, in light of Chairman Cummings’s recent boast that his investigation has affected pharmaceutical “stock prices”-and the Chairman’s decision to unilaterally release sensitive information obtained by the Committee in another investigation-we feel obliged to inform you about these matters.”
“While we cannot speculate about Chairman Cummings’s motives, we believe the Committee should not pursue an investigation to ‘impact . . . stock prices with regard to drugs’-especially when there is bipartisan interest in real oversight of rising prescription drug prices.”
Full text of the letters can be found here.

2 comments:

Anonymous said...

Cummings is such a tool.

Anonymous said...


Everything related to Cummings is questionable. He soils what he touches.